Ouro Medicines

Defining the future of treatment for people with immune-mediated diseases

USA, United States · Founded 2025 · $120.0M raised

Headquarters
USA, California
Employees
11–50
Founded
2025
Business Model
B2B
Total Funding
$120.0M
Last Round
$120.0M Series AJan 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Ouro Medicines is a clinical-stage biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases. Its lead program, OM336 (gamgertamig), is a BCMAxCD3 T cell engager in a basket study targeting multiple autoimmune conditions, and has received FDA Fast Track and Orphan Drug designations. In March 2026, Gilead Sciences announced an agreement to acquire Ouro for approximately $2.18 billion.

Summary

Ouro Medicines is a Biotech company based in USA, United States, founded in 2025. It has raised $120.0M in total across 1 round, most recently a $120.0M Series A round in Jan 2025. Investors include New Enterprise Associates, TPG Life Sciences Innovation and Norwest Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2025
$120.0M

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ouro Medicines on Indexed.vc
<a href="https://indexed.vc/companies/ouro-medicines"><img src="https://indexed.vc/api/badge/company/ouro-medicines" alt="Ouro Medicines on Indexed.vc" width="260" height="76" /></a>